Targets › IGHE
2 programs from 2 companies in 8 trials: 3 Phase 4, 3 Phase 2, 2 Phase 3; Immunology, Infectious disease, Other; next expected readout May 2028.
Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. (UniProt, P01854)
Open in Phaseline: the race on IGHE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Omalizumab Ig epsilon chain C region inhibitor | IGHE | Phase 3 | Chronic Spontaneous Urticaria; Food Allergy; Asthma; Chronic Sinusitis … | May 2028 |
| Taizhou Mabtech Pharmaceutical | Omalizumab (CMAB007) Ig epsilon chain C region inhibitor | IGHE | Phase 3 | Chronic Spontaneous Urticaria | – |
Chronic Spontaneous Urticaria (2) Asthma (2) Food Allergy (1) Chronic Sinusitis (1) Allergies (1) Asthma in Children (1)
mixed (1), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.